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Although many attempts have been made for the identification of novel molecular-targeted 
therapies for acute myeloid leukemia (AML) patients , heir translation into clinics have proven of 
limited impact. In particular,  the question of effective and curative treatment of elderly patients, 
who are not eligible for stem cell transplantation, still represents an unmet medical need. To answer 
this question, a wide range of immunological theraputic strategies, mostly T-cell based, have been 
proposed and investigated. However, at present the clinical results have been largely unsatisfactory. 
Natural killer (NK) cells have been recently used as a means of adoptive immunotherapy with 
promising clinical results. Based on recent clinical reports and moving from basic immunobiology 
of NK cells, here we discuss some open issues about the clinical translation of NK-based adoptive 





























In the last years, major advances have been made in the understanding of the complex molecular 
and cellular network regulating the growth and the development of acute myeloid leukemia (AML). 
In particular, the pivotal role of immunological bone marrow microenvironment is emerging and a 
wide variety of novel immunological therapies, both p armacological and cellular-based, are 
currently under active investigation in the attempt of harnessing the immune system against 
leukemia (1).  
Natural killer (NK) cells represent a unique subset of circulating lymphocytes, which possess potent 
effector function (2,3). However, differently from T cells, NK cells recognize their targets, 
including tumor cells, in a MHC- and, more importantly, antigen-independent manner (4-6) (Fig.1). 
Although for decades tumor antigen-recognition by T cells has been the hallmark for a full 
characterization of effective anti-tumor cytotoxic T-lymphocytes (CTLs), the identification of 
tumor-associated antigens, which may critically serve as targets for T-cell immunotherapy, has been 
largely unsatisfactory. This finding has limited the curative impact of such therapies when translated 
in the clinical setting. In addition, several pathways and mechanisms have been described which 
potently tolerize T cells within the tumor microenvironment (1). With this in mind, the use of NK 
cells as effector cells against leukemia may offer some interesting advantages over T cells in the 
development of immunological cellular-based therapies. It is known that NK cells play a pivotal 
role in eradicating residual leukemia cells after haploidentical stem cell transplantation (7-10). 
These results have prompted several groups to address th  capacity of adoptive immunotherapy 
with NK cells in controlling leukemia. In particular, Passweg and colleagues demonstrated the 
feasibility of selecting and infusing highly purified, T-cell depleted, NK cells to consolidate 
engraftment in high risk patients with myeloid malignancies treated by haploidentical 
transplantation (11). These data were confirmed by Koehl et al, who reported about infusion of 















ALL and AML relapsed/refractory patients. All patients obtained complete response after NK cell 
infusion, without any GVHD signs or symptoms (12). Lee and colleagues performed a phase I study 
with the goal of augmenting GvL effects without exacerbating GVHD in a cohort of patients with 
high risk myeloid malignancies infused with haploidentical NK cells before stem cell infusion (13). 
More recently, moving from the pioneering study by Miller et al. (14), we and others consistently 
and reproducibly described the safety and feasibility of infusing allogeneic NK cells into AML 
patients outside the transplantation setting (15,16).  We demonstrated that NK cell infusion has the 
potential to prevent disease relapse in a subset of elderly patients with AML (17). These results have 
clearly paved the way for designing a new generation of clinical studies aiming to prove the clinical 
efficacy of NK cell-based immunotherapy in the clinical management of AML patients (18).  
 
Who, when and where?  
Although many attempts have been made for the identification of novel molecular-targeted 
therapies (19), their translation into clinics have proven of limited impact and, consequently, the 
management of AML still relies on aggressive chemotherapy, followed by allogeneic stem cell 
transplantation (SCT) (20). If such approach has the potential to cure young patients, the question of 
effective treatment of elderly patients is still open and unsolved (20). Indeed, although the post-
induction remission rate in fit-to-chemo elderly AML patients ranges from 60 to 85%, the disease 
relapse is still very high, thus reducing overall survival (OS) to 10%. Poor clinical outcome in this 
patient population is due to an increase in unfavorble biological features and in the presence of co-
morbidities, which limit, if not exclude, the possibility of undergoing SCT as a consolidation 
strategy, whenever CR is achieved. The persistence of minimal residual disease (MRD) is the major 
problem and its eradication represents an unmet medical need in these patients.  In this scenario, the 















disease. The proof-of-principle of the capacity of immune cells to eradicate MRD derives from the 
results of allogeneic SCT, which clearly represents an option for relapse prevention (20). NK cells 
play a role in the immune control of tumors. They expr ss activating and inhibitory receptors which 
recognize MHC class I alleles, termed "Killer cell Immunoglobulin-like Receptors" (KIRs) (2). In 
addition to KIR, other receptors recognizing HLA class I exist, as the inhibitory CD94/NKG2A and 
activating CD94/NKG2C recognizing HLA-E molecules. The NK cell receptor repertoire is 
primarily determined by KIR genotype, which is extrmely variable in terms of number and identity 
of KIR gene content, it is clonally distributed and selected in a way that each NK cell expresses at 
least one inhibitory receptor for self HLA otherwise is hypo-responsive (a phenomenon termed 
“education”). NK cells are also equipped with activa ng receptors, including NCR (NKp46, NKp30 
and NKp44), NKG2D and DNAM-1, whose ligands are mainly stress-inducible molecules. This 
great array of activating and inhibitory receptors finely regulates NK cell function. While inhibitory 
mechanisms predominate when NK cells encounter normal autologous cells, tumor cells can be 
susceptible to lysis through a mechanism of “missing elf recognition”, because they down-regulate 
HLA-class I molecules, and/or “induced self recognitio ”, because they up-regulate ligands for 
activating receptors. Data from haploidentical T-cell d pleted SCT show that alloreactive KIR-L 
mismatched NK cells are major anti-leukemia effectors, resulting in the protection of AML patients 
from relapse (7-10). However, the SCT approach has important limitations and it is applicable to a 
minority of elderly AML patients. For these reasons, it is conceivable to exploit the anti-leukemic 
potential of NK cells outside  transplantation as adoptive immunotherapy. In this view, Miller et al. 
(14) first reported the safety and feasibility of adoptive immunotherapy with haploidentical NK 
cells in cancer patients, including AML. Furthermore, Rubnitz et al (16) reported their experience 
with haploidentical NK cell infusion in a cohort of10 childhood AML patients with a 2-year event-
free survival of 100%. Our group has published the feasibility and safety of adoptive 















adult high-risk AML patients, mostly with relapsed or resistant disease (15). Importantly, donor-
versus-recipient alloreactive NK cells were demonstrated in vivo by the detection of donor-derived 
NK clones and adoptively transferred NK cells were alloreactive against recipient’s leukemic cells. 
More recently, we have extended our previous investigation by reporting the biological and clinical 
results of NK cell infusion from haploidentical KIR-L mismatched donors in elderly AML patients, 
who had achieved CR after induction/consolidation chemotherapy. Notably, a significantly higher 
number of donor alloreactive NK cell clones was observed in responders over non-responders. The 
infusion of higher number of alloreactive NK cells was associated with prolonged disease-free 
survival. Therefore, we demonstrated, for the first time, that the size of alloreactive donor NK cell 
repertoire is correlated with reduced relapse rate after NK cell immunotherapy.  
Several papers have reported the capacity of non-engrafting alloreactive cells to  kill leukemia 
without inducing graft-versus-host disease (GVHD) (7,8). Therefore, by coupling limited toxicity, 
with a remarkable anti-tumor activity,  alloreactive cells may change the landscape of AML 
treatment and may represent a viable alternative to allogeneic SCT for elderly patients. 
Indeed, Kottaridis et al. performed a phase I clinical study demonstrating he feasibility and safety 
of haploidentical NK cell infusion in a cohort of hig  risk AML patients not eligible for SCT, while 
Shaffer conducted a phase II trial among myeloid malign ncies patients relapsed after SCT and 
treated with haploidentical NK cells (21, 22). 
We then consider that future trials of adoptive immunotherapy should test the efficacy of 
alloreactive NK cells in the subset of  AML patients not eligible for SCT (especially if  over 60 
years of age), who have achieved CR, as a means for eradicating MRD and preventing disease 
recurrence. Indeed, many clinical trials have demonstrated the power of alloreactivity to treat MRD 















designed multicenter, randomized clinical studies (see below) should be planned to provide 
definitive proof of the efficacy of NK-based cellular therapy. 
 
Donor or recipient? Both, please. 
Several biological factors, both of recipient and donor origin, may be implicated in the therapeutic 
effect of NK cells after infusion into AML patients. When recipient-derived factors were addressed, 
Miller et al (24) demonstrated that NK cell expansio , n vivo, after lymphodepleting chemotherapy 
was positively correlated with the endogenous production of some cytokines, such as IL-15 and IL-
35. Both these cytokines are known to critically regulate NK cell effector function and the increase 
of IL-15 may represent a biomarker for NK cell expansion (15). Moreover, the number of 
circulating T regulatory cells (Tregs) critically influenced the capacity of infused NK cells to expand 
and to kill AML cells. Thus, a better DFS was observed in patients infused with NK cells and 
depleted of Tregs. It is well-known that Tregs play a role in reducing NK cell number and effector 
function (25). In the transplantation setting, mice undergoing allogeneic SCT and previously 
depleted of Tregs, but not CD8
+ T cells, showed an increase of BM graft rejection due to enhanced 
NK cell activity. Such effect was successfully abrogated when CD4+CD25+ Tregs were transferred to 
the microenvironment. At the same time, cyclophosphamide-based lymphodepletion, which is 
commonly used before NK cell infusion, is known to subvert endogenous T-cell repertoire, thus 
skewing the composition of T-cell subsets by increasing Tregs /Teffectors ratio (26).  
In our previous clinical studies (15,17) , we focused our attention on the donor. In particular, we 
extensively characterized the alloreactive NK cell r pertoire, which was correlated with the clinical 
response to NK cell immunotherapy (17). Of note, all donors were selected on the basis of KIR-L 
mismatch with the recipient in the GVH direction. Outside the haploidentical transplantation 















clinical response due to enhanced NK-cell mediated disease control (7,8), few reports clearly 
demonstrate a significant impact of KIR-L incompatibility (27-33). Miller et al, by performing a 
retrospective analysis of responders versus non-responders showed that a better response was 
associated with KIR-L mismatch between donor and recipi nt (14). These results suggested that 
donor alloreactivity may impact on the efficacy of adoptively transferred NK cells. Indeed, our 
results, obtained from a study population of previously selected KIR-L-mismatched donor-recipient 
pairs, indicate that the frequency of alloreactive NK cell donors, and not only  KIR-L mismatch, 
significantly predicted NK cell response. Thus, we provide the proof-of-concept that also in the 
setting of adoptive immunotherapy, donor NK alloreactivity may have an important role. Taken 
together, these data reinforce the concept that both d nor selection as well as recipient-derived 
factors should be taken into consideration to optimize NK cell immunotherapy.  
 
The more the better? The point of a functional NK cell dose 
Several investigations have addressed the issue of  the “therapeutic dose” of selected cell 
populations infused in cancer patients. Specifically, early papers have clearly defined the minimum 
number of hematopoietic CD34+ stem/progenitor cells to be reinfused in patients undergoing 
autologous stem cell transplantation to predict a fast and durable engraftment (34).  Conversely, in 
the setting of allogeneic stem cell transplantation, much efforts have been devoted to select the 
optimal dose (and schedule) of CD3+ T cells to achieve a Graft-Versus-Leukemia (GVL) effect, 
without Graft-versus Host Disease  (GVHD), when donor lymphocytes infusions (DLI) are planned 
for relapsing leukemia (35, 36). However, although the infusion of DLI involves important 
parameters specific for allogeneic stem cell transplantation (e.g. GVL/GVHD balance, male/female 
mismatch, effect on donor cell engraftment, timing of cellular therapy after transplantation), 















therapy. In particular, donor selection, disease stage (i.e. DLI treatment is highly efficient with low 
tumor burden), the choice of the optimal cell dose and the role of multiple infusions. In this view, 
our previous experience has shown that the frequency of alloreactive NK cells is highly variable 
among individuals and, therefore, highly variable doses of alloreactive NK cells were infused (17). 
However, our data demonstrated that a  threshold of >8/100 alloreactive NK clones in the donors 
effectively discriminated patients at lower versus higher risk of relapse after NK cell infusion. 
Indeed, the infusion of >8/100 alloreactive NK clones was associated with better RFS versus 
patients with < 8/100 alloreactive NK clones (mean 43 versus 21.6 months, respectively, p=0.006). 
Moreover, the absolute number of NK cell clones correlated with clinical outcome. In particular, we 
found that better outcome was observed when at least 2 x 105 donor alloreactive NK cell clones/kg 
were infused. Therefore, for future studies we propose the preliminary assessment of donor NK cell 
repertoires in the attempt to collect and infuse doses of functional donor-versus-recipient 
alloreactive NK cells that are in the range of those ur previous studies suggested to be effective at 
eradicating residual leukemia (concept of “functional cell dose”) (Fig. 2). To determine the 
“functional cell dose”, KIR-L mismatched donor alloreactive NK cell repertoire will be evaluated 
through the generation of large numbers of donor all reactive NK clones and cytotoxicity assays 
against recipient target cells, as well as flow cytometry analysis (see below) . Such analysis will be 
performed at baseline, since NK repertoire is known to be stable along time.  Thus, the  number of 
donor versus recipient alloreactive NK cells may become a predictive biomarker for clinical 
response to NK immunotherapy. Moreover, few patients i  our series were infused a second time 
upon relapse and molecular analysis demonstrated the ac ievement of second molecular remission. 
Therefore, one may hypothesize the storage of multiple vials of highly purified alloreactive NK 
















Much ado about methods! 
The methods we used to investigate the alloreactive NK cell repertoire pose some concerns. Indeed, 
they are based on NK cell limiting dilution cloning and 51Cr-release assay, which may be considered 
complex, time-consuming and expensive. For these reasons, one major challenge is to develop  
alternative methods, more widely applicable, while maintaining the same diagnostic potential. 
When monoclonal antibodies are not able to discriminate between activating and inhibitory KIRs, 
some studies showed the alloreactive NK cell repertoir  could be analyzed only in individuals who 
are homozygous for the group A KIR haplotype (37, 38). Subsequently, new anti-KIR antibod es 
were developed that could distinguish inhibitory versus activating KIRs when used in appropriate 
combinations, thus allowing the identification of alloreactive NK subpopulations in all individuals. 
One persistent limitation is that no monoclonal antibody can currently distinguish KIR2DS2 from 
KIR2DL2 cells when both are expressed in the KIR genotype (10). Because of these limitations, in 
previous studies, we decided to use cloning assays. However, one of the endpoints of our future 
studies will be the comparison of functional assays with the phenotypic identification of alloreactive 
NK cell repertoire/CD107 assay, as also proposed by other authors (37, 38, 10). Specifically, to 
define the size of alloreactive NK cell subset, multi-colour cytofluorimetric analysis and appropriate 
anti-KIR and anti-NKG2A mAb combinations will be used to detect NK cells expressing, as 
inhibitory receptor, only the KIR specific for the KIR-L mismatch. Thus, the phenotypically defined 
size of alloreactive cell subset (i.e. NK cells expressing, as inhibitory receptor, only the KIR 
specific for the KIR-L mismatch) will be compared with the frequency of NK cell clones with 
ability to kill patient derived cells (10). 
Moreover, the molecular interactions between NK andAML cells should be fully evaluated by 
phenotypic and functional assays to further optimize cell therapy. In particular, the relevance of NK 















can be variably expressed among different individuals should be addressed for optimal donor 
selection when alternative donors are available, both in alloreactive and non-alloreactive cases. In 
addition, the evaluation of ligands for triggering receptors (e.g. PVR, Nectin-2 and ULBPs) as well 
as possible down-regulation of HLA-class I molecules should be performed on AML cells. 
 
Future directions 
Alloreactive NK cells have been emerging as a potent effector cell population against AML. The 
demonstration of the significant clinical activity of alloreactive purified NK cells without 
stimulating GVHD outside the transplantation setting represents a proof-of-principle for such an 
anti-leukemia effect, which had been previously demonstrated in the context of haploidentical SCT.  
Altogether, published data highlight the pivotal roe of NK cells for the development of novel 
immunological approaches in the clinical management of AML. Nevertheless, several biological 
and immunological issues still require full elucidat on.  Additional correlative biological and 
clinical studies are necessary to fully understand the mechanism(s) NK cells exert to kill leukemia 
cells in the non-transplantation setting. In particular, the careful evaluation of the impact that 
recipient- and donor-derived factors may have in influencing in vivo NK cell activity is an 
important point as well as the utility of multiple infusions. The design of future NK-cell based 
clinical trials, both in the SCT and adoptive immunotherapy settings, should include a correlation 
between clinical results and biological outputs. Indeed, correlative biological studies may make 
possible to identify patients who may really benefit from NK cell immunotherapy, in the attempt to 
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Figure 1. Leukemia recognition and cytotoxicity mechanisms of CTLs and NK cells. CTLs (A) 
and NK cells (B) share most of the cytotoxic effector mechanisms, including perforin /granzyme 
production cytokine release and expression of death signals, such as FAS and TRAIL. However, 
differently from T cells (A), which may also be tolerized within leukemia microenvironment  
through leukemia-derived soluble factors, such as tolerogenic cytokines (IL-10 and TGF-β), or 
inhibitory pathways (PD-1-PD-L1 axis, TIM3), NK cells (B) recognize target cells, including 
leukemic blast, in a MHC- and antigen- independent manner. Other mechanisms (NKG2A/D, 
MICA/B) regulate the activation (and inhibition) ofNK cells. Among them, KIR-KIR-L interaction 
represents a critical activatory/inhibitory pathway, which is fundamental for NK alloreactivity. 
 
Figure 2. Flow-chart for patient management, NK cell donor screening/selection and 
definition of NK alloreactive functional cell dose. The frequency of alloreactive NK cells is 
highly variable among individuals and, therefore, highly variable doses of alloreactive NK cells are 
infused. Since the threshold of >2 x 105/Kg alloreactive NK clones in the donors effectively 
discriminated patients at lower versus higher risk of relapse after NK cell infusion. For future 
studies, along with patient induction/consolidation program, we propose the preliminary assessment 
of donor NK cell repertoires in the attempt to collect and infuse doses of functional donor versus 
recipient alloreactive  NK cells that are in the range of those our previous studies suggested to be 
effective at eradicating residual leukemia (concept of “functional cell dose”). Donors are screened 
with physical examination and laboratory tests, including viral sierology, in order to determine their 
fitness to the apheretic procedure. Patients are treated with standard induction and consolidation 
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1. Alloreactive NK cells have been emerging as potent effectors cell against AML. 
2. Several biological and immunological issues still require full elucidation. 
3. The impact of donor NK alloreactivity is an important point  
4. Future NK trials should correlate clinical results with donor alloreactive NK cell repertoire 
